“…Other recent data are consistent with our finding that vacA genotyping appears to offer little in the way of discrimination with regard to clinical presentation. A MEDLINE search of the English language literature, starting with Atherton's first vacA publication in July 1995 and continuing to July 1998, as well as the present study, identify a number of studies reporting vacA genotyping in patients with peptic ulcer or nonulcer dyspepsia from a number of different countries, including 12 studies from Europe (Portugal, The Netherlands, UK, Germany, France, Sweden) or the United States and 4 from Asia (Japan, China, Taiwan) [7,8,20,[23][24][25][26][27][28][29][30][31][32][33][34]. Overall, the available data concern more than 1500 patients (Table 7).…”